Medimaps expands CARPL partnership, bringing TBS Reveal and RBfracture together on the world’s leading radiology AI marketplace
25/06/2026 -
Press releases
Medimaps Group receives CE MDR certification for TBS Reveal™, bringing opportunistic bone-fragility assessment to routine X-rays
17/06/2026 -
Press releases
Medimaps achieves MDSAP certification, strengthening quality management credentials across five major regulatory markets
28/05/2026 -
Media - Press releases
New Study in The Lancet’s eClinicalMedicine Demonstrates Strong Potential for Identifying Bone Fragility Risk from Routine X-Rays
01/03/2026 -
Media - Press releases
Medimaps Group and Radiobotics Announce Strategic Merger to Expand AI-Driven Musculoskeletal Imaging Portfolio
01/12/2025 -
Media - Press releases
Medimaps Group to Unveil TBS Reveal – Opportunistic Screening AI Software on X-Ray – at RSNA
29/07/2025 -
Media - Press releases
Medimaps Group Collaborates with National Spine Health Foundation to Advance AI-Based Bone Fragility Assessment in Spine Surgery
03/07/2025 -
Media - Press releases
Medimaps Group Launches In Europe TBS Osteo Next-Generation Software For Advanced Bone Microarchitecture Assessment
10/06/2025 -
Media - Press releases
Medimaps Group expands in the U.S. with the launch of TBS Osteo next-generation software for advanced bone microarchitecture assessment
01/05/2025 -
Media - Press releases
SimonMed Launches DEXA + TBS: A New Standard for Bone Health
27/01/2025 -
Media - Press releases
Medimaps Breaks New Ground in Fracture Risk Assessment with FDA Clearance and MDR Certification for TBS Osteo Next Generation Software
27/09/2024 -
Media - Press releases
Award-winning study confirms Medimaps Group new AI software accurately assesses bone fragility from routine X-rays
04/09/2023 -
Press releases
Medimaps Group receives EU certification under the medical device regulation
05/07/2023 -
Press releases
Medimaps Group deep-tech TBS software endorsed by international experts working group to inform osteoporosis management decisions for the benefit of the patient
01/03/2023 -
Press releases
Medimaps Group presents data showing new AI approach enhances osteoporosis diagnosis and monitoring at ECR 2023
28/11/2022 -
Press releases
Medimaps Group appoints Meinhard F. Schmidt as Board Chairman; adds Anne Le Grand and five additional board members
14/11/2022 -
Press releases
Medimaps Group announces partnership with OsteoSys to bring trabecular bone score to Korea’s leading bone densitometry platform
04/03/2022 -
Press releases
Medical reimbursement now available for trabecular bone score (TBS), an advanced medtech solution with artificial intelligence capabilities, for osteoporosis fracture risk assessment
Medimaps Group is certified to ISO 13485:2016 (certificate C831121). TBS Insight is FDA 510(k) cleared and MDR compliant, CE-marked under notified body 2460.
Please note that you are now accessing content reserved for healthcare professionals only. By accepting, you confirm that you are a healthcare professional.
Click “OK” to confirm you are a Healthcare Professional.